Core Viewpoint - Harmonic has received a binding offer from MediaKind to acquire its Video Business segment for approximately $145 million in cash, which is expected to close in the first half of 2026, subject to regulatory approvals and employee consultation processes [1][2][3] Group 1: Transaction Details - The proposed acquisition is valued at around $145 million in cash [1][7] - The transaction is anticipated to close in the first half of 2026, pending regulatory approvals and a consultation process with the French employee works council [1][2] - Harmonic's Video Business will be integrated into MediaKind, which aims to enhance its product solutions and innovation capabilities [3][7] Group 2: Strategic Implications - This divestiture will allow Harmonic to sharpen its focus on its core Broadband business and growth priorities [2][3] - The transaction is expected to provide a significant capital infusion, improving Harmonic's balance sheet and financial flexibility [2][3] - MediaKind's acquisition of Harmonic's Video Business is seen as a strategic move to strengthen its position in the video delivery market and enhance its research and development capabilities [3][7] Group 3: Company Background - Harmonic is recognized as a leader in virtualized broadband and video delivery solutions, enabling high-quality video streaming and broadcast services globally [6][8] - MediaKind is a prominent player in the video technology landscape, serving over 2,000 global service providers and content owners [9]

Core Insights - KALA BIO, Inc. has entered into a $6 million securities purchase agreement with private investor David E. Lazar for non-voting convertible preferred stock, with an initial investment of $1.8 million received [1][3] - Following the investment, David E. Lazar has been appointed as the new Chief Executive Officer and Chairman of the Board, while former CEO Todd Bazemore remains on the Board [1][3] - KALA plans to continue the evaluation and redevelopment of its product candidates, particularly KPI-012, despite previous setbacks in clinical trials [2][3] Investment and Financials - The investment agreement includes a second closing contingent on stockholder approval, which is expected in the first quarter of 2026, involving an additional $4.2 million investment [3] - KALA has issued new shares of non-voting convertible Series AA preferred stock in exchange for the initial investment [3] Clinical Development - KALA's KPI-012 did not meet the primary endpoint in its Phase 2b clinical trial for treating persistent corneal epithelial defect, leading to a temporary halt in its development [2] - The company aims to explore strategic options and continue evaluating its therapeutic candidates for potential standalone uses or in combination with other products [2] Company Overview - KALA BIO, Inc. focuses on innovative therapies for rare and severe eye diseases, utilizing its proprietary mesenchymal stem cell secretome platform [4] - KPI-012 has received Orphan Drug and Fast Track designations from the FDA for treating persistent corneal epithelial defect [4]